The 900-patient MultiSENSE trial of Boston Scientific Corp.'s planned HeartLogic heart failure diagnostic service shows that the alerts that it provides for physicians treating heart failure patients are highly sensitive and timely predictors of future heart failure events.
MultiSENSE's lead investigator John Boehmer, from the The Penn State Hershey Medical Center in Pennsylvania, presented the results at the American
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?